Publications & Posters

Scientific Publications and Posters

We continue to validate, strengthen and leverage our single-cell platform with world leaders and pioneers in immunology and cancer research. Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.


We continually author and publish advancements in our work through high impact peer-reviewed journals

Presentation / Posters

We proudly showcase our work through scientific posters and presentation as top conferences

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1.

HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer

The Nature Genetics publication describes a novel high-throughput single-cell ChIP-seq approach to studying heterogeneity of chromatin states within complex biological systems. Our proprietary single-cell CelliGO platform and unique DIS capabilities were used to probe why certain disease cells are resistant to available therapeutics.

Shared Insights About Guiding Principles of Open Collaboration in Drug Discovery Today From HiFiBiO CEO Liang Schweizer and COO Jeff He

Guiding principles of value creation through collaborative innovation in pharmaceutical research HiFiBiO CEO Liang Schweizer and COO Jeff He outline the importance of breaking down common barriers in collaborations, propose four guiding principles for such co-operation and offer a framework to reach value inflection points quicker.

HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, MA – April 27th, 2022 – HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today that clinical trial investigator, Alexander I Spira, MD, PhD, FACP, Co-Director of the Virginia Cancer Specialists (VCS) Research Institute and Director of the Thoracic and Phase I Program, will present a Trials in Progress Poster for HFB200301 on Sunday, … Continued

HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment

Presenters: Juying Li, Qian Zhang, Bingqing Shen, Manan Shah, Mingjie Chen, Sharon Li, Ling Dong, Francisco Adrian, Liang Schweizer

Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors

Presenters: Roshan Kumar, Julie Prigent, Hombline Poullain, Ayrin Kök, Carine George, Sami Ellouze, Yun-Yueh Lu, Rebecca Silver, Clarisse Monchecourt, Ross Fulton, Qian Zhang, Nicola Beltraminelli, Bernhard Moser, Francisco Adrian, Liang Schweizer

Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization

Presenters: Dean Lee, Monika Manne, Roshan Kumar, Rebecca Silver, Alexandra Staskus, Julianna Crivello, Zhiyuan Wang, Dohyun Lee, Ross Fulton, Zhizhan Gu, Christos Hatzis, Francisco Adrian, Andreas Raue, Liang Schweizer

Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody

Presenters: Ross Fulton, Jinping Gan, Yun-Yueh Lu, Julianna Crivello, Zachery Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Wenhua Xu, Xing Cai, Joyce Pi, Dean Lee, Monika Manne, Ruina Jin, Yuan Wang, Hongkai Zhang, Nicola Beltraminelli, Francisco Adrian, Robert Petit, Liang Schweizer, Andreas Raue HFB301001 is being developed … Continued

HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers

Presenters: Germain Margall, Muriel David, Julie Prigent, Dean Lee, Wenhua Xu, Joyce Pi, Xing Cai, Tengfei Wang, Ouyang Li, He Zhou, Andreas Raue, Nicola Beltraminelli, Mingjie Chen, Jia Wu, Mingfang Feng, Angelo Paci, Julia Delahousse, Véronique Saada, Stéphane de Botton, Pierre Busson, Stephanie Beq, Francisco Adrian, Liang Schweizer, Yun-Yueh Lu HFB2009 program focuses on developing … Continued

Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer

Presenters: Shuo Wei, Ross Fulton, Yun-Yueh Lu, Qian Zhang, He Zhou, Andreas Raue, Mingjie Chen, Wenhua Xu, Xing Cai, Juliana Crivello, Zachary Duda, Zhiyuan Wang, Rebecca Silver, Alexandra Staskus, Charina Ortega, Sami Ellouze, Carine George, Sophie Foulon, Dean Lee, Monika Manne, Nicola Beltraminelli, Jinping Gan, Francisco Adrian, Liang Schweizer, Jennifer Watkins-Yoon HFB200301 is an anti-TNFR2 … Continued

Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas

Presenters: Ayrin Kök, Germain Margallducos, Stephanie Beq, Clarisse Monchecourt, Hombline Poullain, Muriel David, Sami Ellouze, Carine George, Mingjie Chen, Yun-Yueh Lu, Juying Li, Qian Zhang, Jean Wang, Adam Woolfe, Louise Gody, Francisco Adrian, Liang Schweizer, Nicola Beltraminelli HFB1002 program focuses on the development of monoclonal antibodies against human CXCR5 as a novel treatment for B-cell … Continued

HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment

Presenters: Roshan Kumar, PhD, Senior Director, Head of Discovery Biology and US External Innovation and Yun-Yueh Lu, PhD, Project Leader, Principal Scientist, Disease Biology HFB2009 program focuses on developing anti-Gal-9 neutralizing antibodies as a potential first-in-class treatment for AML and solid tumors, both as a single agent and a combination therapy. More information about these … Continued

Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment

Presenters: Francisco Adrian, PhD, Senior Vice President, Head of Research and Shuo Wei, PhD, Project Leader, Principal Scientist, Disease Biology HFB200301 is an anti-TNFR2 monoclonal antibody being developed as a potential first-in-class therapeutic for the treatment of biomarker-selected patients with advanced cancer. More information about these and other programs in the HiFiBiO Therapeutics pipeline is … Continued